Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
Top Cited Papers
- 1 September 2003
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 362 (9386), 767-771
- https://doi.org/10.1016/s0140-6736(03)14283-3
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)Circulation, 2001
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Vasoconstrictor Effect of the Angiotensin-Converting Enzyme–Resistant, Chymase-Specific Substrate [Pro 11 D -Ala 12 ] Angiotensin I in Human Dorsal Hand VeinsCirculation, 2001
- Guidelines for the diagnosis and treatment of chronic heart failureEuropean Heart Journal, 2001
- Trends in hospitalization for heart failure in Scotland, 1990–1996. An epidemic that has reached its peak?European Heart Journal, 2001
- Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and designJournal of Cardiac Failure, 1999
- Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart FailureCirculation, 1999
- Functional and Biochemical Analysis of Angiotensin II–Forming Pathways in the Human HeartCirculation Research, 1997
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureNew England Journal of Medicine, 1991
- Angiotensin II-forming pathways in normal and failing human hearts.Circulation Research, 1990